我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

罗格列酮对肥胖患者脂肪细胞中脂联素表达的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第5期
页码:
570-574
栏目:
基础研究
出版日期:
2011-10-25

文章信息/Info

Title:
Effects of rosiglitazone on adiponectin expression in cultured adipocytes of obese patients
作者:
靳 温1孙 璐1廉 坤1贺 媛1夏 炜2陶 凌1王海昌1
第四军医大学西京医院:1.心血管内科,2.整形外科,陕西 西安 710032
Author(s):
JIN Wen1 SUN Lu1 LIAN Kun1 HE Yuan1 XIA Wei2 TAO Ling1 WANG Hai-chang1
1.Department of Cardiology, 2.Department of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China
关键词:
前脂肪细胞脂联素肥胖罗格列酮
Keywords:
human preadipocyte adiponectin obesity rosiglitazone
分类号:
R151.1
DOI:
-
文献标识码:
A
摘要:
目的:探讨噻唑烷二酮类药物(thiazolidinediones,TZDs)罗格列酮(rosiglitazone,RSG)对肥胖患者脂肪细胞中脂联素表达的影响。方法: 依据检查者的体质量指数(BMI)分为正常体重者和肥胖者,各3例。脂肪组织采用整形外科吸脂手术(供者知情并同意)获得。分离培养6例检查者的前脂肪细胞,用胰岛素、地塞米松、三碘甲状腺原氨酸(T3)及3-异丁基-1-甲基黄嘌呤(IBMX)诱导其分化为成熟的脂肪细胞。实验分为对照组和RSG处理组,前者培养的脂肪细胞不进行处理;后者的脂肪细胞用10 mol/L的RSG分别处理12 h、24 h、48 h和72 h。收集细胞的培养上清液,用ELISA法检测脂联素蛋白分泌的水平。提取细胞的总RNA,用RT-PCR法检测脂联素mRNA表达的水平。结果: 肥胖患者成熟脂肪细胞脂联素mRNA及其蛋白表达的水平较正常体重者明显降低(P<0.05)。与对照组相比较,RSG组成熟脂肪细胞脂联素mRNA和其蛋白表达的水平在处理不同时间(12 h、24 h、48 h和72 h)后均明显增高(P<0.05或P<0.01),且呈时间依赖性;但肥胖患者脂联素mRNA和其蛋白表达水平增高持续的时间较正常体重者短(P<0.05或P<0.01)。结论: RSG在一定程度上能增加肥胖患者成熟脂肪细胞中脂联素表达的水平。
Abstract:
AIM:To investigate the effects of rosiglitazone (RSG) on adiponectin expression in cultured adipocytes of obese patients. METHODS: Subjects were divided into two groups: normal body weight and obese subjects according to body mass index. Adipose tissue was obtained after informed consent from adult patients undergoing elective liposuction in the Department of Plastic Surgery. Human preadipocytes were isolated and cultured for several days and then induced to differentiate into adipocytes with special culture medium supplemented with insulin, dexamethasone, T3 and IBMX. Adipocytes were randomly divided into control group and RSG group. Adipocytes in RSG group were then treated with RSG at a final concentration of 10 mol/L for different time durations (12, 24, 48 and 72 h). Adiponectin concentrations in the supernatant were measured by ELISA, and the adiponectin mRNA expression of adipocytes was tested by RT-PCR. RESULTS: Adiponectin mRNA expression and protein secretion were significantly decreased in obese patients compared with patients of normal body weight (P<0.05). Compared with control group, adiponectin mRNA expression and protein secretion in RSG group significantly increased in a time-dependent manner (P<0.05 or P<0.01). However, duration of the increase in obese patients was shorter than in patients of normal body weight (P<0.01). CONCLUSION: To some extent, RSG increases adiponectin expression in cultured adipocytes of obese patients.

参考文献/References

[1]Scherer PE,Williams S,Fogliano M,et al.A novel serum protein similar to C1q, produced exclusively in adipocytes[J].J Biol Chem,1995,270(45):26746-26749.

[2]Szmitko PE,Teoh H,Stewart DJ,et al.Adiponectin and cardiovascular disease: state of the art?[J].Am J Physiol Heart Circ Physiol,2007,292(4):H1655-H1663.

[3]Maeda N,Takahashi M,Funahashi T,et al.PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein[J].Diabetes,2001,50(9):2094-2099.

[4]Abbasi F,Chang SA,Chu JW,et al.Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes[J].Am J Physiol Regul Integr Comp Physiol, 2006,290(1):R139-R144.

[5]Ouchi N,Shibata R,Walsh K.Cardioprotection by adiponectin[J]. Trends Cardiovasc Med,2006,16(5):141-146.

[6]Arita Y,Kihara S,Ouchi N,et al.Paradoxical decrease of an adipose-specific protein,adiponectin,in obesity[J].Biochem Biophys Res Commun,1999,257(1):79-83.

[7]Dervisoglu E,Eraldemir C,Kalender B,et al.Adipocytokines leptin and adiponectin,and measures of malnutrition-inflammation in chronic renal failure: is there a relationship?[J].J Ren Nutr,2008,18(4):332-337.

[8]熊晓坊,李 屏,董晓雁.血清脂联素水平与冠脉病变严重程度有关[J].心脏杂志,2010,22(2):234-236.

[9]Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J].N Engl J Med,2007,356(24):2457-2471.

[10]Kubota N,Terauchi Y,Kubota T,et al.Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways[J].J Biol Chem,2006,281(13):8748-8755.

[11]Tao L,Wang Y,Gao E,et al.Adiponectin:an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction[J].Circ Res,2010,106(2):409-417.

备注/Memo

备注/Memo:
收稿日期:2010-11-08.基金项目:国家自然科学基金项目资助(2009AA02Z104) 通讯作者:王海昌,主任医师,主要从事冠心病的研究Email:wanghc@fmmu.edu.cn 共同通讯作者:陶凌,主任医师,主要从事糖尿病心肌缺血再灌注损伤的研究Email:lingtao2006@gmail.com 作者简介:靳温,硕士生Email:jinw2009@gmail.com
更新日期/Last Update: 2011-11-03